Evidence has been obtained that a single protein, known to modulate classical complement activation, also acts as an inhibitor in the properdin or alternate complement pathway. A highly purified inactivator of the third component of complement (C3) from human serum inhibited the proteolysis of Factor B in the properdin system (glycine-rich j8-glycoprotein) by glycine-rich j3-glycoproteinase. The inhibition was by the enzymatic destruction of glycine-rich j0-glycoproteinase activity. The major fragment of C3, C3b, which is the only known substrate of the C3 inactivator, blocked the destruction of glycine-rich j-glycoproteinase by the C3 inactivator.
The complement (C) system consists of several serum proteins that, on activation, engage in sequential limited proteolysis, and thereby effect many reactions of the local inflammatory response. Activation of the third component of complement (C3) may occur either through the first three components of the "classical" pathway, C1, C4, and C2, or through a group of proteins comprising the properdin or "alternate" pathway. Three known inactivators brake and modulate the classical and common pathways at the C1 (1), C3, and C6 steps (2) . The C3 inactivator is a proteolytic enzyme that destroys the hemolytic and immune-adherence activities of cell-bound, activated C3 (2) in the form of EAC (1)4(2)3.
This same protein may also act as conglutinogen-activating factor (KAF), converting bound C3 into a form that reacts with the bovine-serum protein, conglutinin (3) . The C3 inactivator does not cleave native C3, but does act in the fluid phase on the major cleavage fragment of C3 produced by complement activation, C3b (4, 5) .
A protein isolated from human serum has been designated glycine-rich P-glycoprotein (6) , (GBG) , and has the activity of Factor B (7) of the properdin system (8) . This protein was subsequently isolated from normal human serum by G6tze and Muller-Eberhard (9, 10) , who termed it the C3 proactivator. An enzyme (GBGase) capable of cleaving GBG (11, 12) and destroying its activity as Factor B (8) was identified in the serum of a patient with a complex disorder (type I essential hypercatabolism of C3) affecting the properdin system and C3 (4, 13, 14) . The same enzyme has recently been found in normal serum by Mufller-Eberhard and Gotze (15) and designated C3 proactivator convertase. An inhibitor of GBGase has been identified in normal serum (11, 12) and partially characterized as a 5-6S P-pseudoglobulin.
The present report provides evidence that the C3 inactivator also acts as GBGase inhibitor, that 03b inhibits this reaction, and that the patient with type I essential hypercatabolism of C3 is homozygous for an inherited deficiency of C3 inactivator.
MATERIALS AND METHODS
Preparation of GBG. GBG was purified from fresh human plasma (6) . Monospecific antiserum was produced in rabbits.
Preparation of CS Inactivator (KAF). KAF was purified (3, (11, 12) in all experiments. This serum was devoid of detectable GBG (14) and KAF (4 for assessment of GBGase activity. GBGase action on GBG was stopped at desired times by addition of EDTA to 10 mM and chilling at 4°. Antigen-antibody crossed electrophoresis (18) was used to estimate GBG conversion in essentially the same manner as was used for C3 conversion (19) . The area of the GBG peak divided by the area of GBG plus the area of its a-mobility conversion product multiplied by 100 gave the percent GBG remaining after various treatments. Fig.  1 shows some of the antigen-antibody crossed electrophoresis patterns.
Chemical and Physical Treatments. KAF was heated or treated with 2-mercaptoethanol, iodine, iodoacetamide, potassium periodate, or hydrazine (3). In addition, the effect of treatment of KAF for 10 min at 370 with soybean trypsin inhibitor (1 mg/ml), heparin (1 U/ml), tranexamic acid (1 mg/ml), and p-toluenesulfonyl L-arginine methyl ester (20 mM) was studied.
Gel Filtration. Gel filtration was on a 100 X 2. at various concentrations and for various times with GBGase. As is evident from Table 1 , KAF was fully effective in destroying GBGase at a concentration 0.2% of that in normal serum when incubated for 20 hr at 37°. GBGase in the absence of KAF was fully active against GBG when incubated under the same conditions. This suggested that the inhibition of GBGase by KAF was by proteolytic digestion.
Of the substances and treatments tested for their ability to inhibit the action of KAF on GBGase, soybean trypsin inhibitor, tranexamic acid, p-toluenesulfonyl L-arginine methyl ester, and hydrazine had no effect. Heparin at a concentration of 1 U/ml inhibited GBGase to some extent, but did not inhibit KAF action on GBGase. 2-Mercaptoethanol at a concentration of 10 mM was ineffective, but was inhibitory at a concentration of 100 mM. Potassium periodate (5 mM), iodine (1 mM), iodoacetamide (20 mM), and heating at temperatures of 54°or higher for 30 min partially destroyed the activity of KAF on GBGase. Since C3b in solution is a KAF substrate, it seemed possible that it is a competitive inhibitor of KAF in its action on GBGase. Accordingly, crude C3b was prepared by filtration of the patient's serum through Sephadex G-200; the serum contained about 22 mg of the C3 fragment per 100 ml and 8 mg of native C3 per 100 ml. Table 2 shows the effects of various concentrations of C3b on KAF inhibition of GBGase. It is apparent that C3b is an inhibitor of KAF action on GBGase. Incubation of GBGase with added C3b in the absence of KAF resulted in undiminished GBGase activity.
KAF Concentrations in Serum of Family Members of the Patient with Type I Essential Hypercatabolism of C3. Serum concentrations of KAF in the patient, his mother, six of his eight siblings, and several nieces and nephews are given in Table 3 . His father was unavailable for testing. It is apparent that his mother, three of his siblings, and two nephews had 
DISCUSSION
These observations provide evidence that the C3 inactivator (KAF) (2, 3) is the same as GBGase inhibitor (11, 12) . It is apparent that this enzyme not only attacks cell-bound (2) and fluid-phase (4, 5) C3b, thereby inhibiting the action of C3 on later-acting complement components, but it acts in two ways to inhibit the properdin or "alternate" pathway. C3 inactivator destroys GBGase, thus inhibiting the attack on GBG or Factor B. It has recently been shown that a fragment of C3, probably C3b, is necessary for activation of the properdin pathway (15, 20) . The C3 inactivator may further inhibit the activation of the properdin system by cleavage and inactivation of this fragment (Fig. 3) .
The inhibition by C3b of the proteolysis of GBGase by C3 inactivator suggests that the active enzymatic site on the C3 inactivator is the same for C3b and GBGase. The fact that the same physical and chemical agents, for the most part, inhibit or destroy the action of the C3 inactivator on C3b, whether cell-bound (3) or in solution (4) , as in the case of GBGase, supports this hypothesis. The minor differences in the effects of these agents may be attributed to differences in the sensitivity of the respective assays.
There have been difficulties in explaining the multiple abnormalities, which are seemingly unconnected, in the patient with Type I essential hypercatabolism of C3 (4, 13, 14) , although it has been shown by Nicol 
